Transmembrane signaling by the epidermal growth factor receptor (EGFR) involves ligand-induced dimerization and allosteric regulation of the intracellular tyrosine kinase domain. Crystallographic studies have shown how ligand binding induces dimerization of the EGFR extracellular region but cannot explain the ''high-affinity'' and ''low-affinity'' classes of cell-surface EGF-binding sites inferred from curved Scatchard plots. From a series of crystal structures of the Drosophila EGFR extracellular region, we show here how Scatchard plot curvature arises from negatively cooperative ligand binding. The first ligand-binding event induces formation of an asymmetric dimer with only one bound ligand. The unoccupied site in this dimer is structurally restrained, leading to reduced affinity for binding of the second ligand, and thus negative cooperativity. Our results explain the cell-surface binding characteristics of EGF receptors and suggest how individual EGFR ligands might stabilize distinct dimeric species with different signaling properties.
INTRODUCTION
Receptor tyrosine kinases (RTKs) in the epidermal growth factor receptor (EGFR/ErbB/HER) family play pivotal roles in animal development and in disease (Hynes and MacDonald, 2009; Jorissen et al., 2003; Shilo, 2005) . In particular, EGFR and ErbB2/HER2/Neu are mutated or overexpressed in several human cancers (Hynes and MacDonald, 2009; Sharma et al., 2007) . These facts have motivated the development of tyrosine kinase inhibitors (erlotinib, gefitinib, and lapatinib) and monoclonal antibodies (including trastuzumab and cetuximab) used to target these receptors in cancer patients, plus intensive efforts to understand their signaling mechanisms.
Although it is well known that EGF induces dimerization of its receptor (Yarden and Schlessinger, 1987) , precisely how this leads to EGFR activation is not yet fully understood (Jura et al., 2009; Lemmon, 2009) . Crystal structures of unligated ErbB receptor extracellular regions (Ferguson, 2008) and of ligand-bound dimers of the EGFR extracellular region (Garrett et al., 2002; Ogiso et al., 2002) have revealed large conformational changes that are crucial for ligand-induced dimerization. A key ''dimerization arm'' is buried by an intramolecular ''tether'' in the unligated receptor (Bouyain et al., 2005; Cho and Leahy, 2002; Ferguson et al., 2003) and becomes exposed in the ligand-bound ''extended'' configuration, allowing it to mediate the majority of receptor/receptor interactions in the dimer (Garrett et al., 2002; Ogiso et al., 2002) .
Disappointingly, all binding/dimerization models derived from the crystal structures of EGFR extracellular regions Klein et al., 2004) fail to account for the characteristic curvilinear (concave-up) Scatchard plots that were first described for EGF binding to its cell-surface receptor 30 years ago (Magun et al., 1980; Shoyab et al., 1979) . These concave-up Scatchard plots can signify either negative cooperativity or heterogeneity of binding sites. Traditionally, the latter interpretation has been assumed for EGFR-leading to the notion that this single gene product gives rise to independent (and much-discussed) ''highaffinity'' (K D $0.3 nM) and ''low-affinity'' (K D $2 nM) classes of EGF-binding site at the cell surface (Schlessinger, 1986) . The molecular differences between these proposed classes of binding site, and how they could arise from a single EGF receptor protein, are far from clear. Recent data argue that Scatchard plot curvature reflects negative cooperativity rather than distinct classes of binding site (Macdonald and Pike, 2008; Macdonald-Obermann and Pike, 2009) . Neither view can be reconciled, though, with published biophysical studies of the isolated human EGFR extracellular region (s-hEGFR), and several reports have invoked a requirement for other unknown cellular components (Klein et al., 2004; Wofsy et al., 1992) .
Here we describe the structural basis for negatively cooperative ligand binding to an isolated EGFR extracellular region, revealing how this can occur in the absence of other cellular components-as an intrinsic property of the receptor. Our studies exploit the finding that-unlike its human counterpartthe EGF receptor from Drosophila melanogaster (dEGFR) retains negative cooperativity in ligand binding (and concave-up Scatchard plots) when its extracellular region is studied in isolation. Because the dEGFR extracellular region (s-dEGFR) retains key ligand-binding characteristics previously seen only for intact EGF receptors in cell membranes, it provides a unique opportunity to understand their structural basis. We describe crystal structures of s-dEGFR bound to its growth factor ligand Spitz, which show how occupying one binding site in a receptor dimer impairs ligand binding to the second site in an asymmetric complex-providing a structural explanation for the origin of negative cooperativity. Our structures allow us, in effect, to visualize directly the longsought-after high-affinity and low-affinity ligand-binding sites of an EGFR family member (although they are not independent). These findings also have important implications for understanding how EGFR ligands with different receptor-binding affinities may elicit distinct sets of cellular responses.
RESULTS AND DISCUSSION
The Ligand-Induced Dimer of the dEGFR Extracellular Region Is Asymmetric The key to understanding negatively cooperative growth factor binding to the Drosophila EGF receptor lies in the asymmetry of the Spitz-induced s-dEGFR dimer shown in Figure 1A . We crystallized a form of s-dEGFR bound to the EGF-like domain of Spitz (A) The (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer is asymmetric. Domains I, III, and IV are blue, yellow, and red, respectively. Domain II is green in the left-hand molecule (II L ) and dark gray in the right-hand molecule (II R ). Bound ligand is magenta. The domain II dimerization arm is labeled. An asterisk marks the amino-terminal part of domain II where asymmetry is most evident. (B) Structure (PDB ID code 1IVO) of the symmetric EGF-induced dimer of the human EGFR extracellular region (s-hEGFR) lacking domain IV (Ogiso et al., 2002) , colored as in (A).
(C) Overlay of the left (green) and right (red) molecules from the s-dEGFRDV dimer, using domain I as reference. A double-headed curved arrow illustrates ''wedging'' apart of domains I and III in the green molecule compared with the red molecule, breaking direct domain I/III interactions detailed in Figure S1 , and altering the domain II conformation so that the dimerization arm is substantially reoriented.
(D) Overlay of the right-hand molecule from the asymmetric s-dEGFRDV dimer (red) on unligated s-dEGFRDV (cyan) from PDB ID code 3I2T ), using domain I as reference.
(E) Overlay of the two receptor molecules in the human (EGF) 2 ,(s-hEGFRDIV) 2 dimer. See Table S1 for crystallographic statistics.
(Spitz EGF ; encompassing residues 48-105), and determined its structure to 3.2 Å resolution (see Table S1 available online). The overall domain architecture of s-dEGFR is very similar to that in human EGFR , with which it shares 39% sequence identity over domains I-IV. The ''solenoid'' domains I and III contact the same bound growth factor molecule in ligandstabilized dimers of Drosophila ( Figure 1A ) and human ( Figure 1B ) sEGFR. Domains II and IV are cysteine-rich laminin-related domains, and domain II harbors the dimerization arm that drives core receptor/receptor contacts in both dimers. The complete dEGFR extracellular region contains an additional cysteine-rich domain of $150 amino acids that is absent in hEGFR (domain V, which resembles domains II and IV). Previous small-angle X-ray scattering studies of s-dEGFR showed that domain V projects as a linear extension from the domain IV C terminus . Removing domain V (to yield s-dEGFRDV) was essential for crystallization of the ligand,receptor complexes reported here. Whereas ligand-bound dimers of the human EGFR extracellular region ( Figure 1B) are symmetric, the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer shows clear asymmetry ( Figure 1A ). This asymmetry is most evident at the dimer interface, close to the domain II amino terminus (marked with an asterisk in Figure 1A ). Indeed, significant differences in the relationships between domains I, II, and III are seen when the two subunits from the s-dEGFRDV dimer are overlaid in Figure 1C (the left-hand molecule from Figure 1A is colored green, and the right-hand molecule is red)-yielding an overall root-mean-square deviation (rmsd) in Ca positions of 3.4 Å . Figure 1D further shows that the right-hand molecule of the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 complex (red) closely resembles the unligated s-dEGFRDV structure (cyan) that we recently described , overlaying with a Ca position rmsd of just 1.3 Å . Ligand binding has therefore not altered the domain I/III relationship in the right-hand molecule of Figure 1A . Direct interactions between these two ligand-binding domains that stabilize the unligated conformation are retained-but remodeled in detail ( Figure S1 ). By contrast, upon binding to the left-hand subunit (green in Figure 1C ), Spitz EGF ''wedges'' itself between the two ligand-binding domains and pushes them apart, as indicated by the double-headed arrow in Figure 1C , to break the direct domain I/III interactions seen in unligated s-dEGFRDV (Figures S1A and S1C). Moreover, separating domains I and III with this ''ligand wedge'' distorts domain II (which connects them) and forces a substantial reorientation of the dimerization arm ( Figure 1C ). By distorting domain II in only one of the two s-dEGFRDV molecules in the dimer (the left-hand one), ligand binding induces the marked asymmetry seen in Figure 1A and allows formation of a more extensive (asymmetric) dimer interface than would otherwise be possible. Indeed, as described in detail later, the asymmetric dimer interface in Figure 1A buries a total surface area of 3396 Å 2 , some 33% greater than the 2553 Å 2 buried between the two nearly identical subunits of the symmetric human s-EGFR dimer (which overlay with a Ca position rmsd of just 0.8 Å , as shown in Figure 1E ).
Inequivalence of the Two Ligand-Binding Sites in the dEGFR Dimer Suggests Cooperativity One important consequence of asymmetry in the (Spitz EGF ) 2 , (s-dEGFRDV) 2 dimer is that the two ligand-binding sites differ significantly from one another (Figure 2A ), whereas the two binding sites in the human s-EGFRDIV dimer are almost identical ( Figure 2B ). Differences between the two ligand-binding sites in the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer are most apparent where Spitz EGF contacts domain I. Figure 2A shows the two s-dEGFRDV molecules from Figure 1A overlaid using the bound ligand as reference (the left-hand molecule from Figure 1A is colored green, and the right-hand molecule is red). By wedging domains I and III apart, Spitz EGF has shifted domain I of the green molecule toward the top left corner of the figure by 3-5 Å compared with its position in the red s-dEGFRDV molecule, and has displaced the Nterminal a helix of domain I by $7 Å along its axis (see green arrows in Figure 2A ). Because of this shift in domain I position, its interactions with Spitz EGF are significantly altered in detail when the red and green sites are compared (upper inset in Figure 2A ), although they involve similar sets of dEGFR residues.
The domain III/Spitz EGF interface is less altered between the two binding sites (lower inset of Figure 2A ). The change in domain III position with respect to bound ligand is small, and is mostly compensated for by small adjustments in rotamer positions of interfacial side chains. In a few cases, dEGFR side chains appear to replace one another functionally in the two domain III/Spitz EGF interfaces. For example, in the interface between Spitz EGF and the green binding site, the H433 side chain (underlined in Figure 2A ) assumes the position occupied by E460 in the red binding site. Similarly, E400 substitutes spatially for S401 when the Spitz EGF -binding surfaces of the green and red binding sites are compared (Figure 2A , lower inset).
These differences in the way that Spitz EGF interacts with the two binding sites in the asymmetric s-dEGFRDV dimer can also be thought of as a displacement of ligand on the domain I and III surfaces, as illustrated in Figure S2 . In this view, it is clear that the Spitz EGF A, B, and C loops all make significantly different contacts with the receptor in the two binding sites. Only the location of the Spitz EGF C terminus on domain III is fixed between the two sites ( Figure S2B ), consistent with previous studies that point to the C termini of other EGF-like ligands as major determinants of binding affinity (Groenen et al., 1994) .
As mentioned above, the red binding site in Figure 2A reflects s-dEGFRDV in a conformation that is unchanged from the unligated receptor ( Figure 1D ), whereas forming the green binding site requires the ligand to wedge apart domains I and III. When Spitz EGF binds to the green (wedged-open) site, a total surface area of 4030 Å 2 is buried, compared with just 3730 Å 2 in the red (unaltered) site. Moreover, binding to the green site involves four additional predicted hydrogen bonds between ligand and receptor (an increase of 16% over the red site). Thus, the green s-dEGFRDV molecule shown in Figure 1C and Figure 2A (the left-hand subunit in Figure 1A ) has characteristics expected for a higher-affinity site. By contrast, the red s-dEGFRDV molecule in Figure 1C and Figure 2A (the right-hand subunit in Figure 1A ) appears to be restrained in an unligated-like conformation, which may in turn compromise ligand binding so that this site has a lower binding affinity.
Negatively Cooperative Ligand Binding Can Be Recapitulated with s-dEGFR
The structural inequivalence of the two Spitz EGF -binding sites in Figure 1 and Figure 2 prompted us to ask whether distinct classes of binding site (or negative cooperativity) can be detected in studies of Spitz EGF association with the isolated dEGFR extracellular region. We linked s-dEGFR molecules via their flexible C termini to a solid support to approximate their arrangement at the cell surface while allowing dimerization. An AviTag sequence was introduced (via an unstructured linker) at the s-dEGFR C terminus to allow enzymatic biotinylation of the protein and its capture on the surface of streptavidin-coated 96-well plates (see Experimental Procedures). Spitz EGF was labeled with Alexa Fluor 488 to monitor its binding to surfacebound s-dEGFR. The representative binding curve in Figure 3A cannot be fit satisfactorily with a simple hyperbola, but fits well to the Hill equation (red curve) with a low Hill coefficient (n H ) of 0.31 that suggests negative cooperativity (the mean n H value for all experiments was 0.38 ± 0.07, with a microscopic dissociation constant of 49.5 nM). Transformation of these data into a Scatchard plot ( Figure 3B ) also reveals characteristic concave-up curvature of the sort seen for human EGF binding to its intact receptor at the cell surface. Parallel experiments using a nondimerizing s-dEGFR mutant confirm that this behavior requires s-dEGFR dimerization, and showed simple hyperbolic binding curves ( Figure 3C ) and linear Scatchard plots ( Figure 3D ) with a best-fit n H value of 1.02 (0.97 ± 0.1 over all experiments) and a K D value of 0.92 mM.
Our studies of Spitz EGF binding to dimerization-competent s-dEGFR that has been purified to homogeneity are consistent with the negative cooperativity seen for human EGF binding to its intact cell-surface receptor (Macdonald and Pike, 2008; Wofsy et al., 1992) . Importantly, whereas isolating the human EGFR extracellular region abolishes Scatchard plot curvature (Lax et al., 1991; Lemmon et al., 1997; Livneh et al., 1986; Odaka et al., 1997) , our results show that this is not the case for Drosophila EGFR. Concave-up Scatchard plots do not prove negative cooperativity, however. Indeed, the curves in Figures  3A and 3B can alternatively be fit by assuming the superposition of two hyperbolae that correspond to distinct (and independent) classes of binding site-as has traditionally been done for EGF binding to its cell-surface receptor. In such a fit for Figures 3A and 3B, a high-affinity site (K D $4.7 nM) could account for $65% of the saturated Spitz EGF -binding signal, and an independent lower-affinity class of sites (K D $1.3 mM) could account for the rest. It seems unlikely that molecular heterogeneity is responsible for the Scatchard plot curvature seen for s-dEGFR. Indeed, these experiments were performed with highly purified protein. Figure S2 ). The green structure corresponds to the left-hand molecule in Figure 1A , and the red structure to the right-hand molecule. Green arrows denote the $3-5 Å shift of the green domain I toward the top left of the figure and the $7 Å translation of the N-terminal helix described in the text. A, B, and C loops of the bound ligand are labeled. The upper inset details s-dEGFRDV side chains that interact with Spitz EGF , highlighting significant changes. The lower inset gives a similar view of domain III interactions, which are only modestly changed. Residues underlined (E400, S401, H433, and E460) are mentioned in the text. (B) Analogous overlay of the two bound ligands in the human (EGF) 2 ,(s-hEGFRDIV) 2 dimer from Figure 1B (Ogiso et al., 2002) , illustrating similarity of the two binding sites. Most side chains that contact bound ligand overlay very well in this superimposition. Figures 3A and 3B represent negatively cooperative binding of Spitz EGF to s-dEGFR dimers, as suggested independently by the features of the asymmetric (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer structure (and bindingsite inequivalence) discussed above. It is also important to note that, both for s-dEGFR in our studies ( Figure 3 ) and for intact EGFR in cells (Macdonald and Pike, 2008) , dimerization is required for the appearance of high-affinity ligand binding and for the manifestation of negatively cooperative ligand binding.
EGF binding to hEGFR) the binding curves in
Half-of-the-Sites Reactivity in a Spitz,s-dEGFRDV Crystal Structure Intriguingly, we also obtained evidence for half-of-the-sites reactivity-the extreme of negative cooperativity-in crystallographic studies of s-dEGFRDV bound to a variant of Spitz EGF (Spitz EGFDC ) with a C-terminal truncation that reduces its affinity for the receptor by $12-fold ( Figure S3 ). Crystals that diffracted to 3.4 Å grew from a 1:1.2 mixture of s-dEGFRDV and Spitz EGFDC , and molecular replacement (MR) identified excellent solutions for two s-dEGFRDV molecules in the asymmetric unit. One was found using unligated s-dEGFRDV (or the right-hand molecule in Figure 1A ) as the search model. The other could only be found in MR searches using the left-hand s-dEGFRDV molecule from Figure 1A in which domains I and III are wedged apart. Unfortunately, a marked anisotropy in all data sets made full refinement of this structure impossible. We therefore used only rigid-body refinement, treating each domain of the two sdEGFRDV molecules as an independent body (see Experimental Procedures). For domains I and III, this seems well justified by the absence of ligand-induced structural changes in the individual domains of dEGFR or other ErbB receptors (Ferguson, 2008) . For domains II and IV, major structural changes may be missed with this approach-but we do not expect them.
The rigid-body refined structure of the Spitz EGFDC ,sdEGFRDV complex ( Figure 4A ) suggests a dimer with the same asymmetric arrangement of receptor molecules as seen in the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer discussed above, despite the fact that the crystal packing is quite different in the two cases. Most importantly, whereas one receptor molecule showed clear electron density for bound ligand in 2F o À F c maps ( Figure 4B ), the other showed none ( Figure 4C )-even at very low contour levels. The absence of ligand from this second site cannot be explained by competing crystallization contacts. Thus, Spitz EGFDC appears to induce the formation of a singly ligated asymmetric s-dEGFRDV dimer in these crystals, depicted in Figure 4A . The left-hand (ligated) molecule in Figure 4A has the same conformation as the left-hand molecule in the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer in Figure 1A , with domains I and III wedged apart by the bound Spitz EGFDC . The right-hand molecule in Figure 4A has the same conformation as unligated s-dEGFRDV, and its binding site is empty (or at least has very low occupancy). In parallel studies with Vein, a weak dEGFR activator (Schnepp et al., 1998) with binding affinity even lower than that of Spitz EGFDC (data not shown), we determined a 3.4 Å rigid-body-refined structure that also shows a singly occupied asymmetric dimer. These apparently singly ligated s-dEGFRDV dimers suggest half-of-the-sites reactivity, where binding of Spitz EGFDC (or Vein EGF ) to one site in the s-dEGFRDV dimer prevents (or greatly impairs) ligand binding to the second site.
Remodeling of the s-dEGFR Dimer Interface upon Ligand Binding
Unlike its human counterpart, the dEGFR extracellular region dimerizes even in the absence of ligand, albeit weakly (K D $40 mM). Moreover, unligated s-dEGFRDV crystallizes as a symmetric (crystallographic) dimer, illustrated in Figure 5A ( Alvarado et al., 2009 ). The interface of this symmetric dimer involves only the domain II dimerization arm, and the N-terminal parts of domain II are splayed apart (Figures 5A and 5B) . The total surface area buried in the unligated dimer interface is just 2262 Å 2 .
Binding of Spitz EGF (or Spitz EGFDC ) enhances s-dEGFR dimerization by approximately 30-fold ), associated with an increase of more than 50% in the surface area buried at the dimer interface (to 3396 Å 2 ). This large expansion of the interface arises primarily from direct contacts between the domain II amino-terminal regions that are seen only in the asymmetric ligand-induced dimer ( Figure 5C ). In binding to the left-hand molecule in Figure 5C , Spitz EGF (magenta) has wedged itself between domain I (blue) and domain III (yellow), causing domain II (green) to become distorted or ''bent.'' The aminoterminal part of domain II in the left-hand molecule effectively ''collapses'' onto its unaltered counterpart (gray) in the righthand molecule, creating an additional set of intimate interfacial contacts ( Figure 5D ). The equivalent domain II regions are splayed apart in the symmetric unligated s-dEGFRDV dimer ( Figure 5B ), presumably restrained by direct interactions between domains I and III of the receptor ( Figure S1 ) that we previously suggested may play an autoinhibitory role ). The additional >1000 Å 2 of surface area buried in the asymmetric dimer is likely to account for the 30-fold ($2 kcal/mol) increase in dimerization affinity observed upon ligand binding.
Formation of the more extensive asymmetric dimer interface seen in Figure 5D arises largely from a ligand-induced kink (of $12
) between modules m4 and m5 of domain II (marked with an arrow in Figure 5B ). Modules m2, m3, and m4 from domain II of the left-hand molecule (green) dock onto the domain II surface (gray) of the neighboring molecule in the dimer, without substantially altering the dimerization arm contacts (mediated by module m5). Side chains from Q189 and R201 (in module m2), plus H205 (in module m3) of the ligand-bound receptor molecule, make polar contacts across the dimer interface. Several additional side chains, including those from P188 and P200 (from module m2) plus L206 and F207 (from module m3) also make van der Waals contacts with the opposing domain II in Figure 5D . Modules m2, m3, and m4 bury a combined surface of 1160 Å 2 in the asymmetric s-dEGFRDV dimer interface (34% of the total interface), allowing an intimate set of receptor/ receptor contacts to extend along much of the length of domain II in this dimer. Interestingly, Q189, P200, and H205 are conserved in hEGFR and human ErbB3. Q189 is also conserved in hErbB4, P200 in ErbB2, and H205 in hErbB2 and hErbB4. R201, L206, and F207 are not conserved in the human receptors. Whereas the domain II amino termini make intimate contacts across the interface of the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer, they contribute little to receptor/receptor contacts in the symmetric human sEGFR dimer ( Figure 1B) , burying just 476 Å 2 (with no contribution from m4). Dimerization arm-mediated interactions are very similar in both Drosophila and human sEGFR dimers (Garrett et al., 2002; Ogiso et al., 2002) . However, additional differences between dEGFR and hEGFR are seen for interactions involving the carboxy-terminal part of domain II (modules m7 and m8). These modules make no direct contact across the interface in ligated human sEGFR dimers, whereas in s-dEGFRDV they interact more extensively in the unligated dimer than in the ligand-induced dimer. As a result (and because Ligand is bound to the left-hand molecule in which domains I and III are ''wedged'' apart, but not the right-hand receptor molecule, which structurally resembles unligated s-dEGFRDV. Spitz EGFDC lacks six amino acids from its C terminus, and binds s-dEGFRDV with apparent K D = 4.37 ± 0.26 mM, 12-fold weaker than the value of 368 ± 23 nM measured for Spitz EGF ( Figure S3 ). (B) Electron density is shown from a 2F o À F c map (blue) contoured at 1.0s, calculated with model phases from the receptor molecules alone. In the region corresponding to the left-hand binding site in (A), clear density for bound ligand is seen. Ca traces for domains I and III are shown in blue and yellow, respectively, in the density and the small part of domain IV seen is colored red. (C) By contrast, the 2F o À F c map suggests no density for bound ligand in the region corresponding to the right-hand binding site in (A). This binding site appears to be vacant in crystals of a Spitz EGFDC ,(s-dEGFRDV) 2 dimer. of changes in the domain II/III relationship), ligand binding actually increases the distance separating the two copies of domain IV in the s-dEGFRDV dimer by approximately 24 Å ( Figures 5A  and 5C ); that is, ligand binding actually appears to drive apart domains IV of the two receptor molecules in the transition from a putative ''preformed dimer'' ( Figure 5A ) to a ligand-activated form ( Figure 5C ). Levitzki et al. (1971) pointed out four possible sources for half-ofthe-sites reactivity in dimeric enzymes. In the first, the two ligand-binding sites are adjacent such that occupation of one site directly occludes the second. This cannot explain negative cooperativity in EGFR, where the two binding sites in the dimer are more than 50 Å apart. Two other models require nonidentical binding sites in unligated dimers that arise either from asymmetric dimerization without ligand or from the existence of distinct subunit classes-neither of which are relevant for dEGFR. The fourth and final model involves a symmetric unligated dimer with two identical binding sites. Ligand binding to one of these sites induces conformational changes that promote asymmetry in the dimer, and restrain the vacant binding site so that its affinity for ligand is reduced. A model of this sort may explain the ligand-binding properties of dEGFR, as illustrated by the gallery of structures presented in Figure 6 .
A Structural Model for Negative Cooperativity in an EGFR Extracellular Region
Before interacting with Spitz EGF , the ligand-binding sites are identical in crystallographic preformed dimers, and presumably monomers, of s-dEGFR ( Figure 6A ). Ligand may bind to either species. In either case, the first (highest-affinity) binding event yields the singly ligated, asymmetric Spitz EGF ,(s-dEGFRDV) 2 dimer shown in Figure 6B . High-affinity ligand binding appears to require receptor dimerization because the s-dEGFR dim-arm mutant shows only low-affinity Spitz EGF binding (Figure 3) . Indeed, formation of the asymmetric interface in Figure 5D will facilitate domain II bending in the left-hand molecule, in turn promoting the wedging apart of domains I and III by the first ligand that binds-and enhancing its affinity.
In the asymmetric s-dEGFRDV dimer formed after the first (high-affinity) binding event ( Figure 6B ), domain II in the unoccupied receptor is subjected to a new set of structural restraints. It can no longer bend to allow Spitz EGF to wedge itself fully into the unoccupied ligand-binding site without disrupting the intimate asymmetric interface between amino-terminal parts of domain II shown in Figure 5D . This interface therefore restricts binding of ligand to the right-hand (unligated) receptor in Figure 6B . When a second ligand molecule does bind to the empty site in this dimer, two scenarios (at the extremes) are possible:
(1) The asymmetric dimerization interface seen in Figure 6B may be left intact. With the conformation of domain II fixed in the right-hand molecule so that it cannot bend, it will not be possible for a ligand to wedge domains I and III apart upon binding. This restriction will necessitate binding of ligand to an unaltered (suboptimal) site-as seen for Spitz EGF binding to the red binding site in Figure 2A . This would explain the reduced binding affinity of the second (right-hand) site in the s-dEGFR dimer.
(2) Alternatively, ligand binding to the second site in the dimer could wedge domains I and III apart exactly as in the first ligand-binding event. The resulting domain II distortion would break the ''extra'' contacts in the asymmetric domain II/domain II interface shown in Figure 5D , effectively ''resymmetrizing'' the dimer. The work required to disrupt the asymmetric domain II/domain II interface will reduce the effective affinity of the second site for ligand. The first of these possibilities is likely to explain why asymmetry is maintained in the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer even after binding of the second ligand ( Figure 6C ). The energetic cost of disrupting the asymmetric dimer interface in Figure 6B presumably outweighs the gain in ligand/receptor interactions that can be achieved by wedging apart domains I and III to optimize the second binding site. The second Spitz EGF molecule therefore binds without altering the s-dEGFRDV structure, and occupies a compromised binding site (red in Figure 2A ) with reduced contact area and fewer predicted hydrogen bonds (and therefore lower affinity). The $12-fold-reduced receptorbinding affinity of Spitz EGFDC appears to prevent this ligand variant from occupying the compromised binding site altogether in our crystals, explaining the half-of-the-sites reactivity seen in the Spitz EGFDC ,(s-dEGFRDV) 2 dimer (Figure 4) .
The second of the possibilities outlined above is likely to explain the symmetry of the fully occupied human s-EGFRDIV dimer illustrated in Figure 6D (Ogiso et al., 2002) . If domain IImediated interactions in the asymmetric (singly ligated) dimer are weaker in human EGFR than in Drosophila, they will be disrupted more readily by binding of a second ligand molecule. There are several reasons to suspect that these interactions are indeed weaker in human EGFR than in its Drosophila counterpart. Whereas the isolated extracellular region of dEGFR retains negatively cooperative ligand binding, contributions from the intracellular region are essential in the case of human EGFR (Livneh et al., 1986; Macdonald-Obermann and Pike, 2009 ). This argues that cytoplasmic domain interactions are required to stabilize the singly ligated intact human EGFR dimers required for negatively cooperative EGF binding, or indeed ErbB (B) Singly ligated s-dEGFRDV dimers are asymmetric. Binding of Spitz EGFDC to the left-hand molecule wedges apart domains I and III (blue and yellow), and thus ''bends'' domain II (green) such that it collapses against its counterpart (gray) in the neighboring right-hand molecule, as in Figure 5D . (C) A second Spitz EGF binds to the singly ligated dimer, and occupies the binding site in the right-hand molecule with no change in s-dEGFR conformation. The intimate dimer interface in (B) restrains domain II in the right-hand molecule, so that domains I and III cannot readily be wedged apart. Thus, the binding event that occurs in going from (B) to (C) involves a compromised set of ligand/receptor interactions as described in Figure 2A , reducing binding affinity (and retaining asymmetry in the doubly ligated dimer).
(D) The dimer of human s-hEGFRDIV formed upon EGF binding is symmetric (Ogiso et al., 2002) , with both ligands bound in the same manner ( Figure 2B) . A symmetric dimer of this sort would form following ligand binding to the dimer in (B) if ligand/receptor contacts were maximized at the expense of contacts in the dimerization interface.
receptor heterodimers ( Figure S4 ). Unlike its Drosophila counterpart, isolated s-hEGFR does not form singly ligated dimers in solution and does not exhibit negatively cooperative ligand binding (Lemmon et al., 1997; Odaka et al., 1997) . However, negative cooperativity can be recapitulated in solution by fusing s-hEGFRDIV to a dimeric IgG Fc domain (Adams et al., 2009 )-as also described for the insulin receptor (Bass et al., 1996; Hoyne et al., 2000) . Studies of such artificial dimers may be needed in order to examine structural details of the singly ligated hEGFR dimer inferred from cellular studies. It is also important to note that the intracellular regions of human EGFR and ErbB4 form asymmetric dimers (Jura et al., 2009; Qiu et al., 2008; Red Brewer et al., 2009) , which may contribute to the stabilization of asymmetric, singly ligated dimers of the intact receptors. Residues in this intracellular dimer interface are not conserved in dEGFR, consistent with an increased reliance on extracellular interactions for negative cooperativity in Drosophila.
Implications for the High-and Low-Affinity Binding Sites for Human EGF Our studies suggest that the proposed high-affinity and lowaffinity classes of EGF-binding site at the cell surface do not reflect distinct EGFR populations. Rather, the characteristic curved Scatchard plots reflect negatively cooperative EGF binding to a single type of receptor species. In the binding scheme illustrated in Figure 6 , the first binding event-leading to the singly ligated dimer in Figure 6B -could be considered as the high-affinity site, and the second (leading to Figure 6C ) as the low-affinity site. Restraints imposed on the second binding site in an asymmetric, singly ligated dimer can explain negatively cooperative ligand binding in a model that closely resembles mechanisms of negative cooperativity and half-ofthe-sites reactivity reported for other multisubunit enzyme systems (Koshland, 1996; Levitzki et al., 1971) . We suggest that studies of the isolated human EGFR extracellular region have failed to recapitulate key receptor/receptor interactions required for its allosteric regulation. Intact human EGFR is reported to self-associate to some extent even in the absence of ligand (Chung et al., 2010; Saffarian et al., 2007) , and is thought to form singly ligated, asymmetric dimers required for negatively cooperative ligand binding at the cell surface (Macdonald and Pike, 2008) . Both of these properties are lost when the human EGFR extracellular region is studied in isolation (Lemmon et al., 1997; Odaka et al., 1997) . A similar problem exists for the insulin receptor, where negative cooperativity in insulin binding is completely abolished when the extracellular region of the receptor is released from the membrane surface (De Meyts and Whittaker, 2002) . By contrast, the isolated extracellular region of the Drosophila EGFR appears to maintain the self-association and allosteric properties of the intact receptor, allowing our studies of s-dEGFR to provide serendipitous insight into the mechanism of its allosteric regulation and structural basis for negative cooperativity.
Conclusions and Perspectives
The origin of concave-up Scatchard plots seen for EGF binding to its cell-surface receptor over the past three decades has been contentious. The molecular nature of the high-affinity and low-affinity EGF-binding sites suggested by these curves has also been a subject of significant debate, although recent work suggests that they reflect negative cooperativity rather than distinct classes of site (Macdonald and Pike, 2008) . The studies described here provide a structural basis for understanding negative cooperativity in ligand binding to an EGF receptor. Our analysis suggests that high-and low-affinity binding sites for ligand do exist, but that they occur in the same dimeric receptor complexes and arise from negative cooperativity rather than from distinct populations or ''classes'' of receptor.
If the curved Scatchard plots seen in studies of cell-surface EGF binding reflect negative cooperativity, how can apparent functional and structural differences between the presumed high-affinity and low-affinity classes of EGF receptors be explained? Early studies with antibodies reported to interfere only with high-affinity or low-affinity sites, respectively, concluded that the high-affinity subclass is necessary for early signaling responses to EGF (Bellot et al., 1990; Defize et al., 1989) . Moreover, the route of EGFR internalization from the cell surface depends on the concentration of ligand used to activate the receptor, suggesting that the high-affinity and low-affinity classes of receptor may be subjected to different endocytic mechanisms (Sorkin and Goh, 2009) . At low EGF concentrations, EGFR internalization is primarily clathrin mediated, whereas clathrin-independent mechanisms appear to dominate when very high EGF concentrations are applied. The negative cooperativity model of Macdonald and Pike (2008) suggests that binding of the second ligand to an EGFR dimer reduces the affinity of the two receptors for one another by $10-fold. Indeed, our s-dEGFR structures show how the second ligand-binding event must either compromise ligand/receptor or receptor/receptor contacts ( Figure 6 ). A weakened, doubly occupied, EGFR dimer could behave quite differently from one with only one site occupied-with altered dynamics and interaction (and dimerexchange) properties that might alter specificity, degree of autophosphorylation, mechanism of internalization, and other outcomes.
Differences in the signaling properties of singly and doubly occupied receptors may also explain the distinct biological outcomes when cells are treated with different agonists for the same ErbB receptor (Wilson et al., 2009) or different concentrations of ligand. For example, EGFR agonists with low receptorbinding affinities (amphiregulin, epiregulin, and epigen) might induce the formation of only (or primarily) singly ligated dimers, whereas EGFR agonists with high affinity for the receptor (EGF, TGFa, betacellulin, and HB-EGF) should be able to occupy both binding sites in the receptor dimer if present at sufficiently high concentrations. As a result, the receptor may be activated (and internalized-and ultimately deactivated) differently in response to the two ligand classes. A difference in signaling outcomes of this sort may be very important where EGFR ligands function as morphogens. Gradients of ligands for the Drosophila EGFR (Spitz, Keren, Gurken, and Vein) function in tissue patterning in many developmental programs in D. melanogaster (Shilo, 2005) . It is not clear how different concentrations of these ligands in morphogen gradients can induce different cell fates, which is crucial for ''interpreting'' the gradients. Our work suggests one possibility. At the gradient peak, where ligand concentrations are high, dEGFR dimers will be fully occupied (with two ligands bound per dimer). By contrast, at the tail end of the morphogen gradient where ligand concentrations are low, only high-affinity sites will be occupied in the receptor dimers-yielding singly ligated dEGFR dimers. If the doubly and singly ligated dimers have different signaling properties and internalization routes, distinct cell fates could be induced in the two regimes of receptor activation. This graded occupation of the two binding sites in the EGFR dimer would be substantially lessened in a noncooperative system.
EXPERIMENTAL PROCEDURES Protein Expression and Purification
Histidine-tagged s-dEGFR proteins were produced by secretion from baculovirus-infected Sf9 cells and purified exactly as described ). An AviTag-encoding sequence was included after the C-terminal histidine tag (see Extended Experimental Procedures) for biotinylating protein for fluorescent ligand binding assays. Spitz EGF and Spitz EGFDC were secreted from stably transfected Drosophila Schneider-2 (S2) cells and purified as described in Extended Experimental Procedures.
Crystallography
Crystals of the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 dimer were obtained using the hanging-drop method, mixing equal volumes of protein (75 mM s-dEGFRDV, 90 mM Spitz EGF ) and reservoir solution (1.5 M NaKPO 4 [pH 6.9] with 4% t-butanol) and equilibrating over this reservoir at 21 C. Crystals grew to $0.5 3 0.3 3 0.15 mm, and were cryoprotected by adding stepwise to the drop sodium malonate (pH 6.9) (mixed with reservoir solution) until a sodium malonate concentration was reached (1.7-2 M) that allowed the solution to freeze clear. Frozen crystals diffracted to 3.2 Å resolution at Cornell High Energy Synchrotron Source (CHESS) beamline F1, and belonged to space group P2 1 2 1 2 1 with unit cell dimensions a = 118.2 Å , b = 124.2 Å , c = 186.5 Å (Table S1 ). The asymmetric unit contained two s-dEGFRDV molecules, with a solvent content of 70.1%.
Spitz EGFDC ,(s-dEGFRDV) 2 dimer crystals (up to 0.5 3 0.2 3 0.2 mm) grew at 21 C using the hanging-drop method from a mixture of purified s-dEGFRDV (Table S1 ). With one receptor/ligand (2:1) complex in the asymmetric unit, solvent content is 68.7%. Diffraction data for Spitz EGFDC ,(s-dEGFRDV) 2 crystals were visibly anisotropic, and were subjected to ellipsoidal truncation to 4 Å in the a* axis and 3.5 Å in the b* and c* axes, and anisotropic scaling (http://www. doe-mbi.ucla.edu/$sawaya/anisoscale) (Strong et al., 2006) . Data were processed with the program HKL2000 (Otwinowski and Minor, 1997) , and structures were solved by molecular replacement (MR) using the program Phaser (CCP4, 1994 ). An MR solution for one molecule in the receptor dimer was found readily for both datasets using coordinates from unligated s-dEGFRDV (Protein Data Bank [PDB] ID code 3I2T) as the search model. The resulting maps showed clear electron density for the second receptor molecule and its bound Spitz EGF or Spitz EGFDC molecule, allowing domains I and III to be placed and domains II and IV to be fit. Initial fitting focused on the Spitz EGFDC ,(s-dEGFRDV) 2 dimer structure, early models of which were used to improve model phases for the (Spitz EGF ) 2 ,(s-dEGFRDV) 2 complex. Cycles of manual building/rebuilding using Coot (Emsley and Cowtan, 2004) were alternated with rounds of refinement employing REFMAC and solvent flattening with the program DM (CCP4, 1994), plus composite omit maps calculated with CNS (Brü nger et al., 1998 ). TLS refinement (Winn et al., 2001 ) was used in later stages, using REFMAC (CCP4, 1994), with anisotropic motion tensors refined for each of the receptor domains and bound ligand molecules.
Although initial maps for the Spitz EGFDC ,(s-dEGFRDV) 2 complex showed clear density for the second receptor molecule and its bound Spitz EGFDC molecule, the quality of the electron density remained poor throughout large areas of this structure during refinement and phase combination, particularly in domains I and III. We therefore re-solved this structure by MR using the refined (receptor-only) coordinates of each receptor molecule in the (Spitz EGF ) 2 , (s-dEGFRDV) 2 complex as independent search models in sequential steps. Both receptor molecules were found readily with Phaser (CCP4, 1994) , and clear Spitz EGFDC density in only one binding site (Figure 4 ) allowed its placement as a rigid body. The coordinates for the MR search model (plus placed ligand) were then subjected only to rigid-body refinement, with each receptor domain (and single placed ligand) as an independent body. R/R free values of 41.0/42.7 were obtained (Table S1 ). Structural figures were generated using PyMOL (DeLano, 2002) .
Receptor Biotinylation and Fluorescent Ligand-Binding Assays
Purified s-dEGFR and s-dEGFR dim-arm were biotinylated, and Spitz EGF was fluorescently labeled with Alexa Fluor 488 using standard procedures detailed in Extended Experimental Procedures. Biotinylated s-dEGFR was captured in Reacti-Bind streptavidin-coated 96-well plates (Pierce) in Tris-buffered saline (TBS) plus 0.5% (w/v) bovine serum albumin (TBS-B). Labeled Spitz EGF in TBS-B was then added at a range of concentrations, both to wells with biotinylated s-dEGFR protein and mock-treated wells, and agitated at 25 C for 2 hr. Total ligand fluorescence per well was then counted in a Tecan Safire-2 microplate reader. The plate was then quickly washed with TBS-B, and the remaining (bound) fluorescent ligand was measured. Specific binding was determined by subtracting from the fluorescence measured for each well containing bound s-dEGFR protein the background fluorescence measured for mock-treated wells subjected to the same labeled Spitz EGF concentration. Background was typically less than 10% of the binding signal for s-dEGFR experiments, and less than 50% (at low ligand concentrations) for s-dEGFR dim-arm experiments. Fluorescence values for (specifically) bound labeled (and free) Spitz EGF were converted to picomoles using a standard curve generated by measuring fluorescence of known labeled Spitz EGF concentrations. 
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